Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
| Older periods | Dec '22 | Mar '23 | Jun '23 | Sep '23 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.14 | 15.88 | 10.38 | 1.41 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.30) | (8.53) | (5.40) | (1.00) | |
P/B ratio |
4.40 | 0.00 | 0.00 | 5.79 | |
Price to Tangible BV |
4.41 | 0.00 | 0.00 | 5.81 | |
EV/Sales |
(0.29) | 12.48 | 8.70 | 0.53 | |
EV/EBITDA |
0.04 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.04 | (1.70) | (1.17) | (0.06) | |
EV/FCF |
0.04 | (1.62) | (1.11) | (0.06) | |
Quick Ratio |
2.43 | 1.78 | 1.29 | 0.87 | |
Current Ratio |
2.62 | 1.93 | 1.55 | 0.98 | |
Net Debt/EBITDA |
2.73 | 2.03 | 1.48 | 0.98 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.16 | 0.23 | 0.25 | |
Operating CF/Net income |
0.49 | 0.36 | (0.98) | (0.46) | |
Capex/Depreciation |
(0.05) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,217.98% | 1,067.40% | 846.94% | 316.76% | |
Selling, General and Administrative Expense of Revenue |
229.65% | 234.00% | 240.97% | 106.68% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
39.08% | 46.14% | 59.73% | 10.60% | |
Graham Net Nets |
0.14 | (0.28) | (0.25) | (0.18) | |
Graham Number |
0.00 | 5.07 | 2.86 | 0.00 | |
Earnings Yield |
(170.54%) | (112.00%) | (110.32%) | (461.54%) | |
Free Cash Flow Yield |
(145.82%) | (48.39%) | (75.37%) | (637.72%) | |
Revenue per Share |
0.04 | 0.02 | 0.02 | 0.04 | |
Operating CF per Share |
(0.39) | (0.23) | (0.23) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.23) | (0.23) | (0.13) | |
Cash per Share |
1.48 | 0.47 | 0.24 | 0.11 | |
Shareholders Equity per Share |
0.29 | (0.51) | (0.26) | 0.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.29 | (0.51) | (0.26) | 0.02 | |
Free Cash Flow |
(14.25) | (17.75) | (17.66) | (9.81) | |
Working Capital |
35.86 | 18.87 | 7.82 | (0.21) | |
Capital Expenditures |
(0.01) | — | — | — | |
Net Current Asset Value |
6.47 | (42.59) | (23.51) | (1.79) | |
EV/EBIT |
0.04 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.29 | — | — | — | |
Average Payables |
5.71 | 7.02 | 4.30 | 7.12 | |
Average Assets |
64.97 | 58.46 | 40.81 | 27.64 | |
Average Common Equity |
26.44 | 0.29 | 5.12 | 8.37 |
Columns are period end dates